Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EH-301 + N-acetylcysteine with riluzole in ambulant ALS patients
2024-519857-13-00Phase 2Authorised
- Sponsor
- Biogipuzkoa Health Research Institute
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing EH-301 + N-acetylcysteine + riluzole with Placebo + riluzole (2 arms). Primary endpoints: Change in ALSFRS-R score and Time to 20% ALSFRS-R reduction. Planned start Apr 2025; status: authorised.
02
Drugs
nicotinamide riboside + pterostilbeneacetylcysteineriluzole
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2024-519857-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519857-13-00.